PMV Pharmaceuticals (NASDAQ:PMVP) Releases Earnings Results, Misses Expectations By $0.08 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) issued its quarterly earnings results on Monday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.08), Zacks reports.

PMV Pharmaceuticals Stock Down 3.6 %

PMVP stock opened at $1.32 on Tuesday. The company has a fifty day simple moving average of $1.43 and a two-hundred day simple moving average of $1.52. The firm has a market capitalization of $68.31 million, a P/E ratio of -1.32 and a beta of 1.46. PMV Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $2.26.

Analyst Upgrades and Downgrades

Separately, Oppenheimer raised shares of PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a research note on Friday, November 8th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, PMV Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $5.50.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.